Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

• Status: Completed
• Trial end date: 2019-03-31
• Target enrollment: 0
• Participant gender: Male

Summary

Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Radium Ra 223 dichloride; Succinylcholine

Criteria

Inclusion Criteria:

• Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart.

• Patients were at least 18 years of age as of the first diagnosis for mCRPC.

• Patients must have received at least one intravenous injection of Radium-223 (Xofigo).

• First injection of Radium-223 must have started between periods

1-January-2014 to 30-June-2014 or 15-November-2014 to present.

• Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.

Exclusion Criteria:

• Patients who received Radium-223 as part in an interventional clinical trial

• Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.